Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful efficacy signals in a subgroup of participants with slow disease progression in its recently completed Phase 3 trial. The therapy also showed consistent reductions in neurofilament light chain (NfL) levels — a biomarker that served as the basis for FDA accelerated approval in ALS, including the recent decision on Tofersen — supporting its potential to pursue a similar regulatory pathway.
Developed by South Korean biotech company CorestemChemon (KOSDAQ: 166480), Neuronata-R® utilizes MSCs derived from a participant's own bone marrow to modulate inflammation, protect motor neurons, and alter the neurodegenerative microenvironment through paracrine signaling. ALS, a rare and fatal disease with no cure, remains one of the most urgent areas of unmet medical need. Neuronata-R® aims to address the disease's complex pathology by leveraging the therapeutic potential of autologous MSCs.
In December 2024, CorestemChemon announced topline results from the ALSummit trial (NCT04745299), noting that the study did not meet its primary endpoint — a combined assessment of function and survival known as CAFS — in the overall patient population. However, a post hoc analysis conducted after the completion of the trial and full data collection revealed significant clinical improvements in a subgroup of patients with slower disease progression. To discuss these findings, the company plans to meet with the U.S. Food and Drug Administration (FDA) later this year to discuss these findings, with the aim of submitting a biologics license application by the end of 2025 and potentially securing accelerated approval by mid-2026.
Subgroup Analysis Supports Targeted Efficacy
The final Clinical Study Report (CSR) confirmed that Neuronata-R® demonstrated statistically significant improvements in key efficacy endpoints among participants with slow disease progression. Recognizing the potential efficacy of Neuronata-R® in early-stage ALS, CorestemChemon stratified participants into slow and fast progressors.
Among slow progressors, Neuronata-R® showed statistically significant improvements across multiple measures — including the primary composite endpoint, CAFS (Combined Assessment of Function and Survival), functional outcomes assessed by ALSFRS-R scores, and respiratory function measured by slow vital capacity (SVC).
Notably, the five-dose treatment arm (Group 2) demonstrated statistically significant improvement in ALSFRS-R scores beginning at Month 9 post-treatment — one month earlier than the two-dose arm (Group 1), which reached significance at Month 10.
This final CSR also included full analyses of CAFS and SVC, which had not been previously disclosed. While CAFS served as the trial's primary efficacy endpoint, SVC is recognized as a clinically meaningful measure of respiratory decline in ALS.
At Month 6, participants in Group 1 receiving Neuronata-R® showed a statistically significant improvement in CAFS (LS Mean 20.95 vs 13.66; 95% CI; p<0.024) compared with placebo. Group 2 also showed improvement (LS Mean 24.78 vs 17.92; 95% CI; p<0.041). In Group 2, significant divergence in SVC compared to the control group emerged from Month 8 post-treatment, suggesting a potential effect in delaying disease progression.
NfL Biomarker Reduction Mirrors Regulatory Precedent
CorestemChemon also highlighted the reduction in NfL levels — a biomarker that served as the basis for FDA accelerated approval in ALS, including the recent decision on Tofersen. In both the two-dose (Group 1) and five-dose (Group 2) arms, NfL levels consistently declined over time. Notably, in Group 2, NfL levels were significantly lower than placebo at both Month 4 and Month 10, suggesting a potential dose-dependent effect.
The consistency between the company's internal analysis and validation by an independent CRO strengthens the reliability of the dataset, which has been incorporated into the final CSR.
"This subgroup analysis lends strong support to a biomarker-driven approval strategy," a company official said. "The consistency of our internal analysis with external CRO validation adds credibility to the dataset and provides a concrete basis for regulatory discussions with the MFDS."
Regulatory Pathway Toward Accelerated Approval
The company views these findings as strategically significant, particularly in light of their alignment with the precedent set by Tofersen, where the FDA granted accelerated approval based on NfL reduction rather than survival benefit — a pathway CorestemChemon now seeks to pursue.
The company plans to request a Pre-BLA or Type C meeting with the FDA in Q3 2025, with the goal of submitting a biologics license application by Q4 2025 and targeting regulatory approval by mid-2026. CorestemChemon will finalize its submission package in collaboration with a global CRO and actively engage with regulatory agencies to pursue worldwide market entry for Neuronata-R®.
Innovative Stem Cell Therapy
Neuronata-R® uniquely addresses the complex mechanisms of ALS by leveraging MSCs derived from the patient's own bone marrow. These cells exert anti-inflammatory and immunomodulatory effects, protect motor neurons, and, through paracrine signaling, secrete trophic factors, cytokines, and extracellular vesicles that modulate the microenvironment and reduce neuroinflammation. By targeting these underlying pathological processes, Neuronata-R ® is designed to interrupt the neurodegenerative cascade.
About Neuronata-R®
Neuronata-R® (Lenzumestrocel), developed and commercialized by CorestemChemon Inc. (KOSDAQ: 166480), is an autologous MSC therapy for ALS patients. The company began ALS research in 2002 and obtained MFDS approval for Neuronata-R® in 2014. To date, it has been administered to more than 400 commercial patients and 190 clinical trial participants with no treatment-related serious adverse events reported.
Neuronata-R® holds Orphan Drug Designation from both the U.S. FDA (2018) and the EMA (2019). CorestemChemon completed a Phase 2 trial (NCT01363401) in 2014 and its Phase 3 trial (NCT04745299) in 2024; the final CSR has been submitted to the MFDS.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
23 minutes ago
- Korea Herald
Seoul shares spike over 1.6% on US rate cut hopes
South Korean stocks closed sharply higher Tuesday amid heightened expectations the US Federal Reserve may soon pivot to monetary easing following an employment shock. The local currency was trading lower against the US dollar. The benchmark Korea Composite Stock Price Index climbed 50.25 points, or 1.61 percent, to close at 3,198.00. Trade volume was a little slim at 270.8 million shares worth 10.9 trillion won ($7.85 billion), with winners far outnumbering losers 684 to 190. Foreigners and institutions net purchased 291.9 billion won and 94.5 billion won worth of local shares, respectively, while retail investors net sold 471.8 billion won. The KOSPI had opened in positive terrain, tracking overnight gains on Wall Street sparked by hopes the Fed may begin cutting its key rate in September to support the economy. The Dow Jones Industrial Average closed 1.34 percent higher on Monday, with the tech-heavy Nasdaq composite climbing 1.95 percent and the S&P 500 rising 1.47 percent. Such hopes were fueled after the US Bureau of Labor Statistics issued a jobs report, which showed the world's largest economy only added 73,000 jobs in July, below the market projection of a 100,000 job gain. "The Fed has been keeping its rate unchanged, citing the steady employment market, but the situation is different now," said Lee Kyoung-min, an analyst at Daishin Securities. Lee Jae-won, an analyst at Shinhan Securities, said investor sentiment was also improved on news reports the ruling bloc may reconsider its push for a tax revision aimed at raising taxes on corporations and stock investors. Market bellwether Samsung Electronics closed 0.29 percent higher at 69,900 won, and its chipmaking rival SK hynix gained 2.13 percent to 263,500 won, reflecting US chip giant Nvidia's 3.62 percent increase Monday. Leading battery maker LG Energy Solution jumped 2.93 percent to 386,500 won, and its smaller rival Samsung SDI shot up 10.22 percent to 213,500 won. Financial shares were particularly bullish, with KB Financial spiking 3.69 percent to 112,400 won and Shinhan Financial surging 3.19 percent to 68,000 won. Major shipbuilders also finished strong, with Hanwha Ocean climbing 1.57 percent to 116,100 won, and HD Korea Shipbuilding shooting up 5.63 percent to 356,500 won. Bio firm SK Biopharm skyrocketed 15.92 percent to 111,400 won on the back of record second quarter earnings driven by strong sales of its new epilepsy medication Xcopri. The state-run Korea Electric Power Corp. increased 2.15 percent to 38,300 won, and defense powerhouse Hanwha Aerospace soared 2.45 percent to 961,000 won. Auto and IT shares were among the few losers. Top automaker Hyundai Motor went down 0.24 percent to 210,500 won, and its sister Kia lost 1.36 percent to 101,400 won. Kakao, the operator of the country's dominant mobile messenger, slid 1.26 percent to 54,700 won, and top internet portal operator Naver dipped 0.22 percent to 232,000 won. The local currency was quoted at 1,388.3 won against the greenback at 3:30 p.m., down 3.1 won from the previous session. (Yonhap)
Korea Herald
4 hours ago
- Korea Herald
MSI Showcases DC-MHS and MGX Server Platforms for Cloud-Scale and AI Infrastructure at OCP APAC 2025
TAIPEI, Aug. 5, 2025 /PRNewswire/ -- At OCP APAC 2025 (Booth S04), MSI, a global leader in high-performance server solutions, presents modular server platforms for modern data center needs. The lineup includes AMD DC-MHS servers for 21" ORv3 and 19" EIA racks, built for scalable and energy-efficient cloud infrastructure, and a NVIDIA MGX-based GPU server optimized for high-density AI workloads such as LLM training and inference. These platforms demonstrate how MSI is powering what's next in computing with open, modular, and workload-optimized infrastructure. "Open and modular infrastructure is shaping the future of compute. With OCP-aligned and MGX-based platforms, MSI helps customers reduce complexity, accelerate scale-out, and prepare for the demands of cloud-native and AI-driven environments." – Danny Hsu, General Manager of MSI's Enterprise Platform Solutions AMD DC-MHS Platforms for Cloud Infrastructure Powered by a single AMD EPYC™ 9005 processor and up to 12 DDR5 DIMM slots per node, MSI's DC-MHS open compute and core compute platforms deliver strong compute performance and high memory bandwidth to meet the demands of data-intensive and parallel workloads. Built on the modular OCP DC-MHS architecture and equipped with DC-SCM2 management modules, these systems offer cross-vendor interoperability, streamlined integration, and easier serviceability, ideal for modern, scalable infrastructure in hyperscale and cloud environments. The CD281-S4051-X2 targets 21" ORv3 rack deployments with 48Vdc power, featuring a 2OU 2-node design and EVAC cooling that supports up to 500W TDP per node. With 12 E3.S PCIe 5.0 NVMe bays per node, it offers high-density, front-access storage for throughput-heavy applications. The CD270-S4051-X4 fits into a standard 2U 4-node 19" EIA chassis, maximizing compute density for environments with limited rack space. Supporting up to 400W air-cooled or 500W liquid-cooled CPUs, and equipped with front-access U.2 NVMe bays, it's built for flexible deployment across general-purpose and scale-out workloads. Built on the NVIDIA MGX modular architecture, the CG480-S5063 is optimized for large-scale AI workloads with a 2:8:5 CPU:GPU:NIC topology. It supports dual Intel® Xeon® 6 processors and up to eight 600W FHFL dual-width GPUs, including NVIDIA H200 NVL and RTX PRO 6000 Blackwell Server Edition. With 32 DDR5 DIMMs and 20 PCIe 5.0 E1.S bays, it delivers high compute density, fast storage, and modular scalability for next-gen AI infrastructure.
Korea Herald
5 hours ago
- Korea Herald
Smart Jelly for Smart Aging: Chula's High-Protein Pudding Takes Global Stage
BANGKOK, Aug. 5, 2025 /PRNewswire/ -- Chulalongkorn University 's "High-Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties," developed by Asst. Prof. Dr. Varanya Techasukthavorn and a team from the Faculty of Allied Health Sciences, won a bronze medal in Geneva, along with a special award from Malaysia. Striking with banana and strawberry flavors, the jelly pudding is easy to consume and provides a high protein content of 7-8 grams per cup to strengthen muscles. It's suitable for the elderly, patients, and those who need additional protein. The team is preparing to scale up to commercial production soon. The "High Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties" by Asst. Prof. Dr. Varanya Techasukthavorn, Department of Nutrition and Dietetics, Faculty of Allied Health Sciences, Chulalongkorn University, and her team won the Bronze Medal at "The 50th International Exhibition of Inventions Geneva," held on April 9-13, 2025, in Geneva, Switzerland, and the Prize of Malaysia delegation from Malaysia Delegation from Malaysia. This marks another remarkable innovation that addresses the needs of an aging society and the elderly people who often face problems with reduced food consumption and difficulty chewing and swallowing. Elderly-Friendly Protein Snack under IDDSI Standards Asst. Prof. Dr. Varanya Techasukthavorn, head of the research team, revealed the origin of this innovation: elderly people often have trouble chewing and swallowing food, which causes them to receive insufficient nutrients, resulting in muscle loss. Continuous research on food for people with swallowing difficulties has led to the development of "46 swallowing training foods based on international IDDSI standards." This sparked requests for ready-to-eat snacks that are high in nutrients and safe to swallow for the elderly. Hence, the "High Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties" was created as a between-meal supplement with delicious flavors that appeal to Thai tastes for elderly people. The product is marketed under the name "Elderine," developed in collaboration with Banpong Novitat Co., Ltd. "The research and development of the high-protein jelly pudding formula took more than 1 year, going through various processes in the laboratory. Experiments were done to modify the texture and enhance nutritional value, adjusting the proportions of raw ingredients and flavors as well as examining the texture. The product was then evaluated by 30 elderly volunteers before undergoing the production technology that best meets the requirements," Asst. Prof. Dr. Varanya stated. 2-in-1 jelly pudding: high-protein and chewable, an innovation for every age Asst. Prof. Dr. Varanya explained the unique characteristic of the newly developed high-protein jelly pudding: "it differs from the jelly pudding sold in the market in that it has a 2-in-1 texture. The ready-to-eat jelly texture maintains its stability on a spoon and can become a soft pudding texture when lightly mashed with a spoon, helping elderly people chew and consume food even without teeth. Moreover, this high-protein jelly pudding contains up to 7 grams of a special whey protein isolate per cup without hardening the texture or making it bitter. It incorporates modified cassava starch with glucose polymer molecules to achieve a low glycemic index, and the texture is optimized with a balanced blend of carrageenan and other gelling agents. Using advanced production technology, the product can be stored at room temperature for up to 6 months while maintaining the same quality and texture. Currently, two flavors have been developed to suit the Thai palate: banana and strawberry. Each cup of jelly pudding provides 70-80 calories of energy and 7-8 grams of easily digestible protein, equivalent to one chicken egg. It serves as a healthy snack that can be consumed up to 2 cups per day. Besides the elderly, the product is suitable for various groups of consumers, e.g., those who have recently had their teeth or wisdom teeth removed, causing difficulty chewing; teenagers who want to increase their protein intake; cancer patients who need a lot of protein supplements; and those who would like to build muscle, etc. This high-protein jelly pudding innovation received support from Dr. Chaiwut Gamonpilas from the National Metal and Materials Technology Center (MTEC), National Science and Technology Development Agency (NSTDA), who conducted an oral tribology test on the texture and slipperiness of the jelly pudding. Toward Medical Food Innovation for the Elderly Currently, this product is in the process of patent application. For the future, Asst. Prof. Dr. Varanya shared plans to register the product as a special-purpose food in the form of medical food. In collaboration with a research team (Asst. Prof. Dr. Pattra Wattanapan from the Faculty of Medicine, Khon Kaen University), a human research study will be conducted to test the effectiveness of the high-protein jelly pudding product on increasing muscle mass in elderly people. The team is also expanding collaboration with a research team from Japan for commercial production of the jelly pudding. It is expected to be available in the market around this coming October. Asst. Prof. Dr. Varanya is committed to studying food products for those with swallowing difficulties, with plans to develop products in other forms, such as Thai desserts for the elderly, as well as functional food products with other added nutrients essential for the elderly, like fiber to help with digestion. For the full release and more images, please visit: Chulalongkorn University has made the world's top 50 university list for employment outcomes, which reflects both the high employment rate and work ability of Chula graduates. The university is also listed as the best in Thailand for the 15th Consecutive Year (since 2009), according to the newly released QS World University Rankings 2024, putting Chula at 211th in the world, up from 244th last year.
